论文部分内容阅读
目的观察美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎(ulcerative colitis,UC)的临床效果。方法选择2013年9月—2014年7月收治的UC患者78例,随机分为对照组和观察组各39例。对照组单纯给予美沙拉嗪肠溶片,1 g/次,4次/d。观察组在对照组的基础上加用双歧杆菌三联活菌胶囊,2粒/次,3次/d。两组疗程均为8周。比较两组治疗前后血清C反应蛋白水平、丙二醛浓度及超氧化物歧化酶活力,比较两组疗效、肠粘膜修复情况、不良反应的发生情况。计量资料组内比较采用配对t检验,组间比较采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果对照组总有效率为74.36%,观察组为94.87%,两组比较差异有统计学意义(χ2=6.303,P<0.05)。治疗后,对照组C反应蛋白水平、丙二醛浓度及超氧化物歧化酶活力分别为(8.76±0.95)mg/L、(7.32±0.61)nmol/ml、(1.36±0.09)U/ml,观察组分别为(6.13±0.72)mg/L、(6.20±0.55)nmol/ml、(1.54±0.12)U/ml,两组比较差异均有统计学意义(t=13.779、8.516、7.494,均P<0.05)。对照组肠粘膜恢复率为20.51%,观察组为43.59%,两组比较差异有统计学意义(χ2=4.768,P<0.05)。对照组不良反应发生率为12.82%,观察组为7.69%,两组比较差异无统计学意义(χ2=0.139,P>0.05)。结论美沙拉嗪联合双歧杆菌三联活菌可增强机体清除自由基的能力,减少肠粘膜细胞损伤,促进肠粘膜恢复,并有效改善患者的临床症状,提高治疗效果,值得临床推广应用。
Objective To observe the clinical effect of mesalazine combined with Bifidobacterium triple viable bacteria in the treatment of ulcerative colitis (UC). Methods Seventy-eight UC patients admitted from September 2013 to July 2014 were randomly divided into control group and observation group, with 39 cases in each group. Control group was given Mesalazine enteric-coated tablets, 1 g / time, 4 times / d. Observation group in the control group based on the use of Bifidobacterium triple live bacteria capsules, 2 capsules / time, 3 times / d. The two groups were treated for 8 weeks. Serum C-reactive protein level, malondialdehyde concentration and superoxide dismutase (SOD) activity were compared between the two groups before and after treatment. The curative effect, intestinal mucosal repair and adverse reactions were compared between the two groups. The data of the measurement group were compared by paired t-test, t-test was used to compare between groups, count data were analyzed byχ2 test, P <0.05 was considered statistically significant. Results The total effective rate was 74.36% in the control group and 94.87% in the observation group. The difference between the two groups was statistically significant (χ2 = 6.303, P <0.05). The levels of C-reactive protein, malondialdehyde and superoxide dismutase in the control group were (8.76 ± 0.95) mg / L, (7.32 ± 0.61) nmol / ml and (1.36 ± 0.09) U / (6.13 ± 0.72) mg / L, (6.20 ± 0.55) nmol / ml and (1.54 ± 0.12) U / ml respectively in the observation group, with significant difference between the two groups (t = 13.779, 8.516, 7.494, P <0.05). The recovery rate of intestinal mucosa was 20.51% in control group and 43.59% in observation group, there was significant difference between the two groups (χ2 = 4.768, P <0.05). The incidence of adverse reactions in the control group was 12.82%, while the observation group was 7.69%. There was no significant difference between the two groups (χ2 = 0.139, P> 0.05). Conclusion Mesalazine combined with Bifidobacterium triple viable bacteria can enhance the body’s ability to scavenge free radicals, reduce intestinal mucosal injury, promote intestinal mucosal recovery, and effectively improve the clinical symptoms of patients and improve the treatment effect, worthy of clinical application.